512
Participants
Start Date
July 31, 2003
Primary Completion Date
January 31, 2009
Study Completion Date
January 31, 2009
Sipuleucel-T
Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with a PAP-GM-CSF. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
APC-Placebo
Each dose of APC-Placebo contains approximately one-third of the quiescent APCs prepared from a single leukapheresis procedure. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
Beth Israel Cancer Center, New York
New York University, New York
Clinical Cancer Center, New York
Mount Sinai School of Medicine, New York
Staten Island Urological Research, Staten Island
New York Medical College, Hawthorne
North Shore Hematology Oncology Associates, East Setauket
Albany Regional Cancer Center, Albany
The Urological Institute of Northeastern New York, Albany
Center for Urologic Care, Bryn Mawr
Jefferson Medical College, Philadelphia
Helen F. Graham Cancer Center, Newark
Lombardi Cancer Center, Washington D.C.
Walter Reid Army Medical Center, Washington D.C.
Myron I Murdock MD LLC, Greenbelt
Chesapeake Urology Associates, Baltimore
Urology of Virginia, PC, Norfolk
Urology of Virginia, PC, Norfolk
Duke University Medical Center, Durham
McKay Urology, Charlotte
Grand Strand Urology, Myrtle Beach
Georgia Urology, P.A., Atlanta
Miami Cancer Center, Miami
Urology Center of South Florida, Miami
Cancer Centers of Florida, Ocoee
Hematology/Oncology Associates of the Treasure Coast, Port Saint Lucie
Cleveland Clinic Foundation, Cleveland
Indiana University, Indianapolis
St. Luke's Hospital Immunotherapy Program, Milwaukee
University of Wisconsin, Madison, Madison
University of Wisconsin, Madison
University of Minnesota, Minneapolis
Mayo Clinic, Rochester
Lutheran General Cancer Center, Park Ridge
Loyola University, Maywood
Rush University Medical Center, Chicago
Midwest Prostate & Urology Health Center, Chicago
Mary Crowley, Dallas
Urology Associates of North Texas, Fort Worth
Baylor College of Medicine, Houston
Rocky Mountain Cancer Center, Denver
University of Utah, Salt Lake City
Nevada Cancer Institute, Las Vegas
Kaiser Permanente Medical Group, San Diego
Sharp HealthCare, San Diego
LLUMC for Molecular Biology and Gene Therapy, Loma Linda
South Orange County Urological, Laguna Hills
UCSF Cancer Center, San Francisco
Sutter Cancer Center, Sacramento
EACRI, Portland
Oregon Urology Specialists, Springfield
Virginia Mason Medical Center, Seattle
Seattle Cancer Care Alliance, Seattle
Wenatchee Valley Medical Center, Wenatchee
Cancer Care Northwest, Spokane
Comprehensive Cancer Center, Palm Springs
USC Keck School of Medicine, Los Angeles
UCLA, Los Angeles
Connecticut Urological Research at Grove Hill, New Britain
Dana-Farber Cancer Institute, Boston
Lahey Clinic (Department of Urology), Burlington
Hackensack University Medical Center, Hackensack
Associates in Urology, LLC, West Orange
University of Cincinnati, Cincinnati
Kaiser Permanente Medical Group, Portland
Can-Med Medical Research, Inc., Victoria
London Health Sciences Centre, London
Urology CURC Scarborough, Scarborough Village
Sunnybrook & Women's College HSC, Toronto
Princess Margaret Hospital, Toronto
Hospital Notre Dame du CHUM, Montreal
Lead Sponsor
Dendreon
INDUSTRY